肾髓质癌:[18F]FDG PET/CT评估病变范围及对治疗管理的影响
本研究回顾性分析49例SMARCB1缺陷型肾髓质癌(RMC)患者的[18F]FDG PET/CT,其中48例呈高FDG摄取。PET/CT在31例中检出解剖影像未发现的额外病灶,促使10例(21%)活跃期患者改变临床管理,表明其有助于评估病变范围并优化治疗策略。
要点
- RMC为高FDG摄取恶性肿瘤,原发灶中位SUVmax 13.4。
- PET/CT在31例中检出解剖影像遗漏的病灶,以骨、淋巴结、软组织为主。
- 额外发现使10例(21%)活跃期患者治疗管理发生改变。
核心结论
- RMC是高度[18F]FDG摄取的恶性肿瘤,PET/CT常检出常规解剖影像遗漏的转移部位,有助于评估病变范围并优化治疗策略。
研究设计与样本
- 单中心回顾性研究,纳入2016—2025年间接受[18F]FDG PET/CT的RMC患者49例,分析异常摄取部位、SUVmax及肿瘤/本底比值,并与30天内解剖影像比较。
主要发现
- 49例中48例PET可见明确FDG高摄取病灶;唯一无高摄取病灶者解剖影像亦无病变证据。
- 23例基线分期PET/CT中15例原发肾肿瘤完整,均FDG高摄取(中位SUVmax 13.4,范围9.5-23.5;中位肿瘤/血本底比值10.7,范围4.2-16.6)。
- 31例PET/CT检出解剖影像未发现的额外病灶,主要累及骨(n=18)、淋巴结(n=13)和软组织(n=11);这些额外发现使10例(21%)活跃期患者临床管理改变。
- 解剖影像未发现PET/CT上不存在的病灶。
临床怎么用
- 对RMC患者可考虑[18F]FDG PET/CT评估病变范围,尤其用于检出骨、淋巴结及软组织转移。
- PET/CT检出解剖影像遗漏病灶时可能改变治疗决策,应结合临床综合判断。
局限性
- 单中心回顾性设计,样本量有限(49例),部分为随访或进展时扫描而非基线扫描。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The value of [18F]FDG PET/CT imaging in the management of SMARCB1-deficient renal medullary carcinoma (RMC), a rare and aggressive type of kidney cancer, has not been established. We sought to determine the utility of [18F]FDG PET/CT findings for the evaluation of disease burden and treatment planning in patients with RMC. Methods: Using an institutional database, we identified patients with RMC who underwent [18F]FDG PET/CT scans as part of clinical care between 2016 and 2025. When available, baseline [18F]FDG PET/CT images were used; otherwise, the earliest available follow-up scan performed because of concern of recurrence or progression was included. For all scans, sites of abnormal [18F]FDG uptake were assessed, the SUVmax of the most avid site was quantified, and tumor-to-normal tissue ratios (TNRs) were calculated. PET/CT findings were compared with anatomic imaging (CT/MRI-based) performed within 30 d. Instances in which PET/CT findings altered treatment were recorded. Results: On PET, 48 of 49 patients had clearly [18F]FDG-avid disease. The single patient without [18F]FDG-avid lesions also lacked evidence of disease on anatomic imaging. Of the 23 patients who received a baseline PET/CT scan for staging purposes, 15 had intact renal primary tumors, and all tumors were [18F]FDG-avid (median SUVmax, 13.4; range, 9.5-23.5; median TNR blood, 10.7; range, 4.2-16.6). Ten patients were imaged during therapy, and 16 underwent imaging after progression or before the start of a new treatment. Forty-three patients had [18F]FDG-avid nodal metastatic disease (median SUVmax, 8.9; range, 1.8-27.0). Extranodal disease was observed in 36 patients, most commonly in the lungs (n = 24; median SUVmax, 5.8; range, 1.7-17.5) and bones (n = 19; median SUVmax,10.7; range, 3.7-24.8). In 31 patients, [18F]FDG PET/CT identified additional lesions not detected on anatomic imaging, predominantly involving bones (n = 18), lymph nodes (n = 13), and soft tissues (n = 11). These additional findings led to a change in clinical management for 10 (21%) of 48 patients with active disease. In contrast, no lesions were identified on anatomic imaging that were not apparent on PET/CT scans. Conclusion: RMC is a highly [18F]FDG-avid malignancy. [18F]FDG PET frequently detects additional metastatic sites missed by conventional anatomic imaging, facilitating disease extent assessment and optimizing treatment strategy in patients with RMC.
引用
- Krebs S, Salem AE, Nguyen NC, et al. Renal Medullary Carcinoma: Utility of [18F]FDG PET/CT in Evaluating Extent of Disease and Impact on Treatment Management. J Nucl Med. 2026. PMID: 42315313. doi:10.2967/jnumed.126.272258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。